|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
British Columbia Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing British ColumbiaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Aurinia Pharmaceuticals Inc.
| | | Phone: | (780) 487-1600 | Fax: | (780) 484-4105 | Year Established: | 1993 | Employees: | 75 | Ticker: | AUPH | Exchange: | NASDAQ | Main Contact: | Michael R. Martin, COO | | Other Contacts: | Lawrence Mandt, VP, RA & QA Dennis Bourgeault, CFO Richard M. Glickman, Ph.D., Chairman & CEO Robert Huizinga, VP, Clinical Affairs Neil Solomons, CMO Rashieda Gluck, VP, Operations
| | Company Description | Aurinia Pharmaceuticals (formerly Isotechnika) is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.
On Sept. 23, 2013 Isotechnika and privately-held Aurinia Pharmaceuticals completed the merger of the two companies, creating a premier clinical stage pharmaceutical company focused on the global nephrology market. | |
|
|
|
|
|